ELP1 Gene Variants in Familial Dysautonomia
- 1Dysautonomia Center, Department of Neurology, NYU Grossman School of Medicine, New York
- 2Department of Genetics and Genomic Sciences, Institute for Genomic Health, Icahn School of Medicine at Mount Sinai, New York, NY; and
- 3Center for Genomic Medicine and Department of Neurology, Massachusetts General Hospital, and Harvard Medical School, Boston.
Abstract
Background and Objectives: Familial dysautonomia (FD), also known as hereditary sensory and autonomic neuropathy type III, is an autosomal recessive disease caused by variants in the elongator acetyltransferase complex subunit 1 (ELP1) gene. The most common pathogenic variant, ELP1 c.2204 + 6T > C (formerly reported as IVS20 + 6T > C), is a founder variant prevalent in the Eastern European Ashkenazi Jewish (AJ) population, and more than 99.5% of patients are homozygous. This pathogenic variant impairs ELP1 pre-mRNA splicing, leading to reduced levels of full-length transcript and resulting in tissue-specific reductions in ELP1 protein. In addition to this founder variant, 2 other variants have been previously reported: the ELP1 c.2087G > C variant identified in 4 unrelated AJ-FD patients, as well as the ELP1 c.2741C > T variant described in a single non-AJ patient. All reported patients with these missense variants were compound heterozygotes carrying the ELP1 c.2204 + 6C > T founder variant. The aim of this study was to report 4 pathogenic variants in ELP1 that were identified in patients with FD who also carry the founder pathogenic variant ELP1 c.2204 + 6C > T.
Methods: Patients referred to the NYU Dysautonomia Center with suspected FD underwent comprehensive evaluations, including clinical assessments, neurologic examinations, and genetic testing.
Results: Four patients were identified as compound heterozygotes for the ELP1 c.2204 + 6T > C founder pathogenic variant and one of 4 novel ELP1 variants: ELP1 c.1361-1G > T, ELP1 c.1229C > T, ELP1 c.2443A > G, and ELP1 c.725C > T. All patients exhibited the full spectrum of FD manifestations. Their self-reported ancestry was diverse: 1 patient was born in Canada to AJ parents, 1 was born in Poland, and 2 were born in the United States, including 1 with African American ancestry; 3 were unaware of any AJ heritage despite carrying the major AJ allele.
Discussion: We report 4 patients who meet clinical criteria for FD and carry the founder pathogenic ELP1 splicing variant in trans with 4 variants previously not associated with the disease. These findings expand the genetic and ancestral spectrum of FD; underscore the importance of considering the diagnosis in patients from diverse backgrounds, including African American patients; and support careful evaluation of rare ELP1 variants during genetic testing when FD is clinically suspected.
Related
- Rare Novel Genetic Variants of the OFD1 Gene Associated With a Familial Form and a Sporadic Case of Long Bone Atypical Fractures
- Non-Coding Structural Variants in Regulatory Regions and High Polygenic Burden May Jointly Contribute to Early-Onset Familial Hashimoto’s Thyroiditis
- Familial dystonic Choreoathetosis associated with Biallelic ATM variants
- Familial, neuropathological and cellular analysis identify ARPP21 as a major amyotrophic lateral sclerosis associated gene in French cohorts
- Impact on venous thrombosis risk of newly discovered gene variants associated with FVIII and VWF plasma levels
BibTeX
@article{kaufmann2026elp1,
title = {{ELP1 Gene Variants in Familial Dysautonomia}},
author = {Horacio Kaufmann and Alejandra Gonzalez Duarte and Kaia Dalamo and Andreana Barnett and Patricio Millar Vernetti and Felicia Axelrod and Chelsea Lowther and Paolo Pigini and Ricardo S. Harripaul and Dadi Gao and Elisabetta Morini and Susan A. Slaugenhaupt},
journal = {Neurology: Genetics},
year = {2026},
month = nov,
doi = {10.1212/nxg.0000000000200463},
url = {https://doi.org/10.1212/nxg.0000000000200463},
note = {CC BY-NC-ND 4.0},
}
RIS
TY - JOUR
TI - ELP1 Gene Variants in Familial Dysautonomia
AU - Horacio Kaufmann
AU - Alejandra Gonzalez Duarte
AU - Kaia Dalamo
AU - Andreana Barnett
AU - Patricio Millar Vernetti
AU - Felicia Axelrod
AU - Chelsea Lowther
AU - Paolo Pigini
AU - Ricardo S. Harripaul
AU - Dadi Gao
AU - Elisabetta Morini
AU - Susan A. Slaugenhaupt
PY - 2026
DA - 2026/11/11
JO - Neurology: Genetics
DO - 10.1212/nxg.0000000000200463
UR - https://doi.org/10.1212/nxg.0000000000200463
AB - Background and Objectives: Familial dysautonomia (FD), also known as hereditary sensory and autonomic neuropathy type III, is an autosomal recessive disease caused by variants in the elongator acetyltransferase complex subunit 1 (ELP1) gene. The most common pathogenic variant, ELP1 c.2204 + 6T > C (formerly reported as IVS20 + 6T > C), is a founder variant prevalent in the Eastern European Ashkenazi Jewish (AJ) population, and more than 99.5% of patients are homozygous. This pathogenic variant impairs ELP1 pre-mRNA splicing, leading to reduced levels of full-length transcript and resulting in tissue-specific reductions in ELP1 protein. In addition to this founder variant, 2 other variants have been previously reported: the ELP1 c.2087G > C variant identified in 4 unrelated AJ-FD patients, as well as the ELP1 c.2741C > T variant described in a single non-AJ patient. All reported patients with these missense variants were compound heterozygotes carrying the ELP1 c.2204 + 6C > T founder variant. The aim of this study was to report 4 pathogenic variants in ELP1 that were identified in patients with FD who also carry the founder pathogenic variant ELP1 c.2204 + 6C > T. Methods: Patients referred to the NYU Dysautonomia Center with suspected FD underwent comprehensive evaluations, including clinical assessments, neurologic examinations, and genetic testing. Results: Four patients were identified as compound heterozygotes for the ELP1 c.2204 + 6T > C founder pathogenic variant and one of 4 novel ELP1 variants: ELP1 c.1361-1G > T, ELP1 c.1229C > T, ELP1 c.2443A > G, and ELP1 c.725C > T. All patients exhibited the full spectrum of FD manifestations. Their self-reported ancestry was diverse: 1 patient was born in Canada to AJ parents, 1 was born in Poland, and 2 were born in the United States, including 1 with African American ancestry; 3 were unaware of any AJ heritage despite carrying the major AJ allele. Discussion: We report 4 patients who meet clinical criteria for FD and carry the founder pathogenic ELP1 splicing variant in trans with 4 variants previously not associated with the disease. These findings expand the genetic and ancestral spectrum of FD; underscore the importance of considering the diagnosis in patients from diverse backgrounds, including African American patients; and support careful evaluation of rare ELP1 variants during genetic testing when FD is clinically suspected.
SN - 2376-7839
ER -